Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest S&P 500 Dividend Aristocrats Target Income UCITS ETF 16.04.2026 KNG.LN IE000SNMGYT5 850,002.00 USD 17,367,186.97 20.432 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - November 16.04.2026 GNOV LN IE000OJ31JQ4 1,050,002.00 USD 37,539,734.42 35.752 ...
-
Seven HKTDC Lifestyle Fairs Power Sourcing and Showcase Hong Kong’s Creative Industries
HONG KONG--(BUSINESS WIRE)--The Hong Kong Trade Development Council (HKTDC) is hosting seven mega events, including Hong Kong Gifts & Premium Fair, Home InStyle and Fashion InStyle (27-30 April at the Hong Kong Convention and Exhibition Centre, HKCEC); the Hong Kong International Printing & Packaging Fair and DeLuxe PrintPack Hong Kong (held concurrently at AsiaWorld-Expo); and the Hong Kong International Licensing Show and Asian Licensing Conference (27-29 April at the HKCEC). These ev...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF- August 16.04.2026 GAUG LN IE000TGSG3Y5 550,002.00 USD 19,819,975.70 36.036 ...
-
Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors
NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today announced multiple scientific disclosures coinciding with the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego, California. The data define an Rb pathway–driven pan-cancer development framework for KIF18A inhibitors and highlight a proprietary p16 IHC biomarker approach designed to transl...
-
Mountain Valley MD Announces Appointment of Advisors and Stock Option Grants
TORONTO--(BUSINESS WIRE)--Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) is pleased to announce the appointment of multiple advisors to the Company as well as the grant of stock options to certain directors, officers, and consultants/advisors of the Company. APPOINTMENT OF ADVISORS The Company has appointed the individuals listed below as advisors to provide strategic advisory services on customary commercial terms, with any compensation subject to applicabl...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Scarce Resources UCTS ETF 16.04.2026 SCAR LN IE000BW2B3J3 50,002.00 USD 1,527,431.03 30.547 ...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...